Showing 6211-6220 of 8707 results for "".
- Evolve BioSystems and Janssen to Study the Impact of B. infantis EVC001 for AD Prevention in Infantshttps://practicaldermatology.com/news/evolve-biosystems-and-janssen-to-study-the-impact-of-b-infantis-evc001-for-ad-prevention-in-infants/2460324/Evolve BioSystems, Inc. and Janssen Research & Development, LLC, are partnering to conduct a study looking at the potential role of B. infantis EVC001 in preventing early childhood atopic dermatitis (AD). The study will assess the effects of introducing a specific gut
- Positive Phase 3 Results Reported for Medimetriks and Otsuka's AD Drughttps://practicaldermatology.com/news/positive-phase-3-results-reported-for-medimetriks-and-otsukas-ad-drug-1/2460322/Medimetriks Pharmaceuticals, Inc. and Otsuka Pharmaceuticals Co. Ltd.’s MM36 (difamilast) performed well in two Phase 3 Japanese clinical trials in adult and pediatric atopic dermatitis (AD) patients. Difamilast is a novel topical, non-steroidal phosphodiesterase IV (PDE4) inhibit
- FDA Greenlights Pfizer’s Eucrisa for Children As Young As Three Months With ADhttps://practicaldermatology.com/news/fda-greenlights-pfizers-eucrisa-for-children-as-young-as-three-months-with-ad/2460321/The U.S. Food and Drug Administration (FDA) gave its nod to Pfizer’s Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis (AD). Eucrisa was previously approved for use in adults and children 2 years of age and older. It is the first a
- Destiny Pharma and MedPharm Complete Initial Phase of Development Projecthttps://practicaldermatology.com/news/destiny-pharma-and-medpharm-complete-initial-phase-of-development-project/2460318/Destiny Pharma and MedPharm have completed the initial phase of their project to develop new topical formulations of Destiny’s novel XF‐platform drugs. Further to forming the collaboration with MedPharm last year, the project has identified a range of new, stable XF formulations w
- CMS Updates Quality Reporting Requirements in Light of COVID-19https://practicaldermatology.com/news/cms-updates-quality-reporting-requirements/2460315/CMS is granting exceptions from reporting requirements and extensions for clinicians and providers participating in Medicare quality reporting programs with respect to upcoming measure reporting and data submission for those programs. For those programs with data submission deadl
- AAD Offers Tips for Practicing in the Era of COVID-19https://practicaldermatology.com/news/aad-offers-tips-for-practicing-in-the-era-of-covid-19/2460313/The American Academy of Dermatology released new guidance for dermatologists amid the COVID-19 crisis including an update on teledermatology and reimbursement codes. The guidance includes: March 19th AAD President’s Message:
- Zylö Therapeutics a Finalist in the Buzz of BIO Contesthttps://practicaldermatology.com/news/zylo-therapeutics-a-finalist-in-the-buzz-of-bio-contest/2460311/Voting ends tonight for the Buzz of BIO contest, sponsored by BIO, the world's largest trade association representing biotechnology companies. Zylö Therapeutics, which has dermatology as one of its focus areas, is a finalist in the “Pipelines of Promise”
- Special Report: An Overview of Coronavirus by Dr. Jonathan Kaplanhttps://practicaldermatology.com/news/special-report-an-overview-of-coronavirus-by-dr-jonathan-kaplan/2460306/Wash your hands, wipe down surfaces, don’t touch your face, and practice social distancing. If nothing else, that’s what you should take away from this coronavirus overview. But keep reading to learn important details about this epidemic. Such as, how we can make it end with less coll
- Dermatologist Urges Vigilance for Exanthem as Coronavirus Spreadshttps://practicaldermatology.com/news/dermatologist-urges-vigilance-for-exanthem-as-coronavirus-spreads/2460304/As the novel coronavirus spreads across the US and the World Health Organization declares a global pandemic, dermatologists may be able to play a role in diagnosing and combating the disease, says New York City dermatologist Bobby Buka, MD, JD. In fact, the cofounder of The Dermatology Specialist
- Viper Equity Partners Seeks to Expand into Florida and Georgia Dermatology Marketshttps://practicaldermatology.com/news/viper-equity-partners-seeks-to-expand-into-florida-and-georgia-dermatology-markets/2460303/Viper Equity Partners is turning its attention to key dermatology and related aesthetics offices in Florida and Georgia to join private equity-backed partnerships. In an effort spearheaded by Senior Vice President Nina Das (see photo), the North Palm Beach-based M&A advisory firm is